Purpose: Treatment options for unresectable paraganglioma (PGL)/pheochromocytoma (PCC), especially with uncontrolled secondary hypertension (HTN), are limited. Preliminary studies with peptide receptor radionuclide therapy (PRRT) suggest efficacy, but data on HTN control and survival are lacking. We assessed PRRT outcomes in such patients from two referral centers.
nervous system, whereas PCC specifically refers to lesions arising from the adrenal medulla. The genomic landscape of these tumors is complex, with both heritable and sporadic driver mutations recognized in at least 20 genes, which influence their clinical behavior (2, 3) . For example, mutations in different subunits of the succinate dehydrogenase (SDH) gene complex are each associated with distinct PGL syndromes. The most common is SDHB, which is often inherited as an autosomal-dominant germline mutation and is associated with a high risk for metastatic disease (4) . In addition, although most parasympathetic PGLs are nonsecretory, PGL and PCC from the sympathetic chain secrete catecholamine. This leads to secondary hypertension (HTN) and other symptoms of sympathetic overactivity (such as headache, sweating, palpitations, tremor, pallor, and anxiety). Complications can include life-threatening acute hypertensive catecholamine crisis and end-organ damage (5) . Therefore, this is a complex disease where site of origin and genotype may influence clinical behavior and prognosis.
Management of PGL and PCC may include close observation in asymptomatic patients. Options for localized progressive disease include surgery, externalbeam radiotherapy, or nonsurgical local ablative therapy (6) . However, treatment options for progressive or symptomatic unresectable metastatic disease are limited. Antihypertensive therapy for functional tumors typically requires alpha-adrenergic blockade (usually with prazosin or phenoxybenzamine), followed by beta-blockade if needed, but these are often poorly tolerated, with substantial side effects leading to long-term adherence issues. Metyrosine, a catecholamine synthesis inhibitor, can be effective but is costly and therefore not readily available in some countries. Oncologic treatment conventionally includes 131 I-metaiodobenzylguanidine (MIBG) therapy for tumors demonstrating high uptake on MIBG imaging (6) (7) (8) . Studies suggest modest effectiveness in disease stabilization or partial responses in .50%, along with improvement of blood pressure indices, symptoms, and performance status (9, 10) . However, its use may be limited by hematologic toxicity (11) and the need for prolonged inpatient admission for radiation safety purposes. Combination chemotherapy using cyclophosphamide, vincristine, and dacarbazine appears to be the most popular regimen for malignant PCC and PGG; however, its antineoplastic effect is limited, with relapse occurring early in most patients (12) . Sunitinib, a tyrosine kinase inhibitor, is considered a potential therapeutic option but has limited activity. A retrospective study using this agent suggested tumor size reduction or stabilization in 47% of patients with progressive disease, but with a median progression-free survival (PFS) of only 4.1 months; of note, .50% of patients in this series experienced no clinical benefits or adverse effects requiring early discontinuation of treatment (13) . Another potential novel molecular target for PGL/PCC is overexpression of cell surface somatostatin receptors (SSTRs).
68
Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptides, including DOTATyr3-octreotate (DOTATATE), DOTA-Tyr3-octreotide (DOTATOC), or DOTA-Nal3-octreotide (DOTANOC), bind to SSTR with high affinity, thereby enabling imaging with positron emission tomography (PET)/computed tomography (CT). Recent studies have suggested high sensitivity and superior imaging characteristics in this population (8, (14) (15) (16) (17) . The different forms of radiolabelled peptides differ in affinity profiles for SSTR subtypes, with 68 Ga-DOTATATE of highest affinity to SSTR 2, 68 Ga-DOTATOC to SSTR 5, and 68 Ga-DOTANOC predominantly to SSTR 3 and 5. The presence of SSTR also allows theranostic application and targeting with peptide receptor radionuclide therapy (PRRT) as a novel treatment approach.
To date, the predominant experience of PRRT is driven from treatment of SSTR expressing gastroenteropancreatic neuroendocrine tumors, with evidence of high therapeutic effectiveness and minimal toxicity (18, 19) . There are limited published data on the outcomes of PRRT in PGL/PCC. Preliminary experience suggests low toxicity and favorable efficacy in disease control (20) (21) (22) (23) (24) . The largest series, of 28 patients with surgically incurable PGL/PCC using 90 Y-DOTATOC or combined with 177 Lu-DOTATOC, showed stable or partial responses in 54% and time to progression of 3 to 42 months (21) . In the most recently published study of 5 patients, the median PFS was 17 months (22) . However, data are lacking on effectiveness of PRRT in controlling secondary HTN and other catecholamine-related symptoms or of biochemical response rates in patients with functional, unresectable local or metastatic disease. Therefore, in addition to assessment of morphologic responses, toxicity, and overall survival (OS), we reviewed clinical, HTN, and biochemical responses in patients with high-SSTR-expression tumors treated with PRRT from two referral centers.
Materials and Methods

Patients
We retrospectively reviewed 20 consecutive patients (13 men and 7 women; age range, 21 to 77 years) with unresectable PGL/ PCC who received 177 Lu-DOTATATE PRRT from the two referral centers with at least 3 months of follow-up from completion of PRRT. Patients were followed up until death or study close-out date of 25 Lu-DOTATATE given 6 to 10 weeks apart. At Peter MacCallum Cancer Centre, the second through fourth cycles were usually given with radiosensitizing chemotherapy unless contraindicated. An earlier protocol used infusional fluorouracil as a radiosensitizer (typically 200 mg/m 2 daily, starting 2 days before PRRT for 2 weeks total). The subsequent regimen, per local institutional protocol for treatment of gastroenteropancreatic neuroendocrine tumors, included the use of oral capecitabine (825 mg/m 2 twice daily commencing 2 days before PRRT for 2 weeks) or combined capecitabine and temozolomide (capecitabine 750 mg/m 2 orally twice daily on days 1 through 14 commencing 9 days before PRRT, with temozolomide 100 mg/m 2 twice daily on days 10 through 14 commencing on the day of PRRT for 5 days). More recently, single-agent oral temozolomide as an effective radiosensitizer for neural-type tumors has been used (100 mg/m 2 twice daily for 5 days commencing on the day of PRRT).
Follow-up
Patients were clinically reviewed before and after each cycle of PRRT, typically at 3 months following the last cycle of treatment. Evaluation at 3 months included assessment of symptoms, doses of anti-HTN medications, molecular imaging ( 68 Ga-DOTATATE PET/CT), and CT. Biochemical marker serum chromogranin A (CgA) was reviewed. Plasma and urine metanephrine levels were not routinely performed at the Hadassah-Hebrew University Medical Center, and because of the paucity of available results these were not included in the overall analysis.
Symptomatic benefit was defined as an improvement in tumorrelated symptoms based on patients' subjective report relative to baseline symptoms. HTN control was documented as the reduction in anti-HTN medication requirements: no change in anti-HTN doses, reduced anti-HTN medication doses, complete cessation of anti-HTN medications, or increased requirement of anti-HTN medications. All medication dosages were recorded where possible. Biochemical response was assessed by comparing serum CgA before and 3 months after PRRT as the percentage change from baseline. Percentage changes in plasma metadrenaline and normetadrenaline levels were described for patients with secondary HTN when results were available.
For molecular imaging, the descriptor for pathologic uptake on 68 Ga-DOTATATE PET/CT has been adapted from a semiquantitative visual scoring system originally designed for planar 111 In-octreotide imaging known as the Krenning score. This score consists of a scale from 0 to 4 and uses liver and spleen as reference organs (score 0 = no uptake; 1 = very low uptake; 2 = lesion uptake less than that of spleen; 3 = uptake greater than that of liver; 4 = uptake greater than that of spleen) (25) . 68 Ga-DOTATATE PET/CT response was defined as stable, partial response (reduction in intensity by 1 Krenning point in at least one tumor site), complete response (total disappearance of abnormal uptake of previously avid lesions), or progressive disease (increase in intensity or extent of previous abnormal uptake or development of new avid lesions). CT response was defined as stable, partial or complete response, or progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (26) . Minor response was also used to describe smaller size changes not meeting partial response on RECIST 1.1 (10% to 30% decrease in maximum diameter of target lesions). Where available, contrast-enhanced CT images were directly compared. Otherwise, nonenhanced CT from PET components of the study were assessed, with scintigraphic uptake used as a guide to follow the dominant lesions. All hematologic and renal toxicities occurring from the time of PRRT administration were recorded. Toxicity is defined according to the Common Terminology Criteria for Adverse Events, version 4.0.
Statistical analysis
The OS and PFS curves were estimated for the total cohort of patients by using the Kaplan-Meier product-limit method (GraphPad Prism 7; GraphPad Software, LaJolla, CA) measured from start of PRRT. PFS was calculated to tumor progression or death from any cause. Progression was defined by symptomatic relapse (for those treated for functional disease) or biochemical recurrence and imaging progression on molecular imaging (SSTR +/2 fluorodeoxyglucose) or RECIST 1.1. These progression criteria are thus more stringent than relying solely on morphologic progression based on RECIST 1.1 alone.
Results
Patient characteristics and treatment parameters
Of the 20 patients treated with 177 Lu-DOTATATE, 7 had SDHB mutation, 1 had SDHD mutation, 2 were negative for mutation, and 10 were of unknown status. HTN and symptom response Fourteen of 20 patients were treated for uncontrolled secondary HTN. One patient was lost to follow-up and therefore the response for 13 patients were reviewed. At 3 months after PRRT, 8 of 13 patients (62%) required reduced doses of anti-HTN medications compared with baseline; the remaining 5 (38%) had no change in medication doses but attained control of HTN. Refer to Tables 2 and 3 for details.
Eight patients with secondary HTN reported improvement in tumor-or hormone-related symptoms at 3 months after PRRT. These included reduced dizziness and lethargy in one patient; reduced pain, headache, and night sweats in one; reduced pain and weight gain in one; reduced bone pain in one; reduced headache, dizziness, pain, and palpitations in one; and reduced pain, headache, and palpitations in one. One patient remained stable and asymptomatic throughout. Two patients reported complete resolution of symptoms, including headache in one and lethargy, night sweats, and constipation in another. Two patients reported worsening symptoms: One had increased pain and shortness of breath; the other had pain, headache, and dizziness (neither had changes in anti-HTN doses).
Biochemical response 3 months after PRRT
For the total patient cohort of 20 patients, 14 had serial CgA results available. Twelve of these 14 patients (86%) had reduction of CgA when compared with baseline, of whom the majority, 58%, had a substantial .50% reduction when compared with baseline ( Fig. 1 and Table 2) .
Of the 14 patients treated for secondary HTN, plasma metadrenaline and normetadrenaline were available for assessment for 7 patients. Plasma metadrenaline decreased by 25% to 50% in 4 patients (57%), decreased by .50% in 1 patient, and increased by 23% and 32% in 2 patients, respectively. Plasma normetadrenaline was reduced by 25% to 50% in 2 patients, decreased by .50% in 4 patients (57%), and mildly increased by 8% in 1 patient. Scan response 3 months after PRRT SSTR Of 17 patients evaluable for SSTR response, 8 (47%) had a partial response, 41% had stable findings, and 12% (2 patients) had progression ( Fig. 1 and Table 2 ).
CT
Images were not available for review for 3 patients; 3 other patients had osseous metastatic disease not evaluable by RECIST 1.1 but well-defined lesions on SSTR molecular imaging. Of the remaining 14 patients, 4 (29%) had partial RECIST response, 1 (7%) minor morphologic regression, 7 (50%) had stable disease, and 2 (14%) had progression ( Fig. 1 and Table 2 ). Of note, of the 7 patients with stable disease on CT, 4 patients were treated for functional HTN (not prior disease progression), 2 patients had stabilization of previously progressive disease, and 1 patient had no objective evidence of previous progression before PRRT.
OS, PFS, and follow-up
Median follow-up, calculated by using the reverse censoring method, was 28 months (range, 5 to 74 months) from start of PRRT. Median OS was not reached (Fig. 2) .
Five patients died before the close-out date. Two patients died of metastatic disease (one had small bowel obstruction from tumor compression; the other had liver failure secondary to extensive disease). One patient had metastatic functional PGL with an initial clinical response and disease control after induction PRRT but developed multiple osseous metastases with extremely high catecholamine levels. This was complicated by acute hypertensive crisis and catecholamine-induced ileus (Ogilvie syndrome) requiring neostigmine and additional cycles of PRRT, which resulted in further favorable but transient clinical, biochemical, and scintigraphic responses. However, disease again relapsed 16 months later; despite further PRRT, this patient died of rapid disease progression 56 months after the first PRRT. One patient died of unknown cause, not related to PRRT. The fifth patient died of cardiac arrest shortly after the third cycle of PRRT, but the exact cause of cardiac arrest was unknown. In this last patient, the indication for treatment was disease progression; however, it appeared that this patient had inadequate workup. The functional tumor had not been documented, and therefore the patient was not receiving alpha-or beta-blockade at the time of therapy. Although the cause of death may be related to potential unrecognized catecholamine crisis, this patient was not noted to be hypertensive at baseline; thus, the cause of death may have been related to other causes, such as massive pulmonary embolism. During follow-up, six patients deteriorated after PRRT, two patients had tumor progression (at 2 months and 5 months from first PRRT), and five patients had recurrence of HTN (at 16 months, 19 months, 39 months, and 61 months from first PRRT). Four of these patients were re-treated with further PRRT ranging from one to eight cycles because of prior clinical response to previous treatments. Two other patients were given further maintenance therapies for persisting disease, with favorable response. The median PFS was 39 months.
One patient responded remarkably to PRRT and underwent subsequent wedge resection of two residual liver lesions with no evidence of disease on repeated scans to date.
Toxicity
Marrow and renal function
Data were unavailable for one patient at 3-month follow-up. The most common toxicity observed was grade 2 lymphopenia. Four patients developed grade 3 lymphopenia, and two patients had grade 3 thrombocytopenia at 3 months. No grade 4 hematologic toxicity, myelodysplastic syndrome, or leukemia was noted.
In terms of renal toxicity, one patient with abnormal baseline renal function developed a further reduction in glomerular filtration rate (GFR) after PRRT, which eventually stabilized during the follow-up, without need for dialysis. Another patient had pre-existing chronic renal failure secondary to systemic amyloidosis thought to be related to underlying metastatic PGL and had already been considered for dialysis because of severely impaired renal function with estimated GFR of 24 mL/min (hence this contraindication was waived). Indication for treatment was for metastatic disease and to potentially control secondary amyloidosis and other related systemic complications. This patient's estimated GFR decreased to 18 mL/min at 3 months after treatment but was considered more likely related to underlying amyloidosis than the one cycle of PRRT. This patient also had documented grade 3 lymphopenia and thrombocytopenia after treatment, likely related to delayed excretion and relatively more prolonged radiation retention and marrow exposure. Peritoneal dialysis was commenced 4 months after PRRT. A second cycle of 177 Lu-DOTATATE was given 7 months after the first cycle, complicated by pancytopenia requiring granulocyte colony-stimulating factor and transfusions, again likely related to slow clearance. Blood counts recovered at 9 months after PRRT, accompanied by a remarkable clinical and imaging response (Fig. 3) .
Clinical
HTN flare was observed in only one patient, who became notably unwell 3 hours after PRRT administration. This patient developed acute loin pain, pallor, sweating, palpitations, and HTN (blood pressure, 200/90 mm Hg) related to acute catecholamine release and possibly exacerbated by dexamethasone premedication, in the context of inadequate alpha-and beta-blockade before treatment resulting from patient nonadherence to prescribed therapy.
Discussion
PGL and PCC are a complex group of tumors with heterogeneous primary sites, imaging phenotype, biology, and genotype. They have a variable clinical course and prognosis. Recent advances in molecular imaging techniques allow detection of different molecular targets on PGL and PCC (27) . Conventional Ga-DOTA-peptide PET/CT is being increasingly performed to assess SSTR expression with high sensitivity, and 18 F-fluorodeoxyglucose PET/CT is being done for glucose metabolism. The presence of a specific molecular target also allows choice in optimal therapy and theranostic application, which is particularly advantageous for patients with multifocal or metastatic disease.
The use of PRRT for patients with PGL and PCC who have high tumor SSTR expression has been reported in several small retrospective series, all with variable study and treatment protocols. Overall results suggest favorable objective disease control, reflected by partial response or stable disease, mainly on the basis of CT criteria. Our results (one of the largest series, with 20 patients) also show similar favorable findings, with 36% of patients achieving PRRT-induced morphologic regression (29% partial CT response and 7% minor reduction). An additional 50% of patients had stable disease at 3 months after treatment. Importantly, however, most of these patients were treated for functional HTN rather than prior progressive disease (three of four patients responded clinically and required reduced doses of antihypertensive medications), others had stabilization of previously progressive disease, and one patient had no prior documented progression, likely indicating an indolent disease process. Therefore, using CT morphologic regression as the sole response criterion may not reflect the true therapeutic benefit for patients with PGL/PCC depending on the indication for treatment.
In addition, up to 15% of patients in our series (three patients) had predominant osseous disease detectable only on molecular imaging and not measurable according to CT criteria. This further suggests that CT alone is inadequate as the standard staging or restaging modality and that molecular imaging provides incremental information for evaluation of disease response.
To our knowledge, this study is to date the largest series assessing the efficacy of PRRT for patients with functional disease and secondary HTN. Most patients (70%, 14 patients) in this cohort were treated for this indication; more than half (62%) could reduce the doses of antihypertensive treatment at 3 months after treatment, and all others had stabilization of blood pressure control. Many patients had improvement of diseaserelated symptoms, particularly reported reduction in dizziness, headache, pain, and lethargy. Biochemical (CgA) reduction was achieved in a high proportion of patients (up to 86%). These findings indicate favorable efficacy in functional disease, providing a very promising therapeutic option for patients with uncontrolled However, special precautions are required in treating patients with functional hypertensive disease, given the potential for initial hormone flare or tumor lysis leading to acute catecholamine crisis; this was seen in one patient in this series and in previous experience, as reported by Makis et al. (28) . Adequate preparation with alpha-and beta-blockade is mandatory, with inpatient monitoring and access to intensive care support if required. Withholding dexamethasone as a premedication should also be considered because this may exacerbate HTN in patients with PGL/PCC (29) . As previously mentioned, one death in this series occurred shortly after the third cycle of PRRT, although the exact cause of cardiac arrest remains unknown; an acute catecholamine crisis was a possibility among other differential diagnoses. This further highlights the need for optimal workup, including alpha-and beta-blockade preparation and best supportive care to minimize acute treatment-related hormone toxicity.
No documented myelodysplastic syndrome or myelodysplasia was noted in this study. Hematologic toxicity was minimal. One patient required long-term peritoneal dialysis due to progressive chronic renal failure, in a setting of known systemic amyloidosis; this patient developed reversible pancytopenia after the second cycle, requiring initial supportive treatments. This likely reflected delayed urinary excretion of administered activity and consequently prolonged blood pool retention and radiation exposure to marrow. Conversely, the high bioavailability of radiolabeled peptide in this case seems to have led to an excellent subsequent clinical and morphologic response.
PRRT also has potential advantages over conventional 131 I-MIBG radionuclide therapy; for example, hematologic toxicity is minimal, and thyroid blockade preparation with Lugol's iodine is not required. PRRT with 177 Lu-DOTATATE has a favorable radiation safety profile, enabling potential outpatient treatment or a shorter inpatient stay (30) . A recent study has suggested increased OS and PFS in patients treated with PRRT compared with 131 I-MIBG therapy in patients with progressive/malignant PGL (31). Our series also showed that the majority of evaluable patients had negative or only mildly MIBG-avid disease on 123 I-MIBG imaging, rendering 131 I-MIBG therapy an unsuitable option for these patients compared with PRRT. Moreover, patients with tumor phenotype showing both or discordant molecular targets may theoretically benefit from a combined or sequential radionuclide therapeutic approach using PRRT and 131 I-MIBG, but further trials are required to assess efficacy and potential toxicity with this regimen. Potential limitations of this study are recognized. The number of patients is small, but this is still considered a relatively large series compared with previous publications, given the rarity of this disease. This is a retrospective review of patients from two international institutions that used similar but not uniform treatment and follow-up protocols. Variability included total administered radiopharmaceutical activity and the use and choice of radiosensitizing chemotherapy administered. Although it is unclear from the limited number of patients of any incremental efficacy using radiosensitizing chemotherapy over PRRT alone, no additional toxicity was apparent with its concomitant use, and therefore radiosensitizing chemotherapy could be considered for incorporation in any future prospective study protocols. Moreover, although the biochemical marker CgA was assessed in most patients, serum or urine catecholamine levels were not routinely measured in one of the centers; this would have been useful as an additional biochemical marker.
Conclusion
In addition to favorable disease control with minimal toxicity from PRRT, our results indicate substantial clinical and biochemical effectiveness in patients with functional metastatic SSTR-positive PCC/PGL. We suggest that initial staging and subsequent response assessment should incorporate molecular imaging because CT alone may underestimate the degree of response, particularly in osseous disease, which commonly occurs in metastatic PCC/PGL. The spectrum of PGL/PCC phenotypes is heterogeneous, and the choice of optimal therapy should include characterization of disease using molecular imaging, previous response to therapy, and minimization of toxicity, given the potential indolent disease course despite functional, multifocal, or metastatic disease. PRRT has potential logistic and radiationsafety advantages compared with conventional 131 I-MIBG therapy. Given the favorable efficacy, further prospective PRRT trials, including use of radiosensitizing chemotherapy, are warranted.
